{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:01:42Z","timestamp":1790798502202,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bmc.2019.115217","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T20:12:23Z","timestamp":1574971943000},"page":"115217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening"],"prefix":"10.1016","volume":"28","author":[{"given":"Fikriye","family":"Ozgencil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokcen","family":"Eren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezen","family":"Guntekin-Ergun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengul","family":"Cetin-Atalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2019.115217_b0005","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1089\/ars.2017.7478","article-title":"Regulation of cancer and cancer-related genes via NAD+","volume":"30","author":"Sharif","year":"2018","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.bmc.2019.115217_b0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bmcl.2015.12.101","article-title":"Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase","volume":"26","author":"Chen","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115217_b0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pharmthera.2015.02.004","article-title":"Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer","volume":"151","author":"Sampath","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2019.115217_b0020","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2016.1190649","article-title":"Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities","volume":"16","author":"Chen","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.bmc.2019.115217_b0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MOG.0b013e32801b3c8f","article-title":"The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt\/PBEF\/visfatin in mammals","volume":"23","author":"Revollo","year":"2007","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.bmc.2019.115217_b0030","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/bies.10297","article-title":"Reconstructing eukaryotic NAD metabolism","volume":"25","author":"Rongvaux","year":"2003","journal-title":"BioEssays"},{"key":"10.1016\/j.bmc.2019.115217_b0035","doi-asserted-by":"crossref","first-page":"8345","DOI":"10.1021\/acs.jmedchem.6b00697","article-title":"Minimizing CYP2C9 inhibition of exposed-pyridine NAMPT (nicotinamide phosphoribosyltransferase) inhibitors","volume":"59","author":"Zak","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115217_b0040","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2174\/1570180814666161110112859","article-title":"Homology modeling of human nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 2: Insights into isoenzyme-specific differences using molecular docking simulatons","volume":"14","author":"Eren","year":"2017","journal-title":"Lett Drug Des Discov"},{"key":"10.1016\/j.bmc.2019.115217_b0045","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601913507576","article-title":"Nicotinamide phosphoribosyltransferase in malignancy","volume":"4","author":"Shackelford","year":"2013","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bmc.2019.115217_b0050","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis","volume":"63","author":"Hasmann","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2019.115217_b0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/CAD.0b013e3283287c20","article-title":"Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777","volume":"20","author":"Beauparlant","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bmc.2019.115217_b0060","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1128\/MCB.00112-09","article-title":"The small molecule GMX1778 Is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors","volume":"29","author":"Watson","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.bmc.2019.115217_b0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10637-007-9083-2","article-title":"The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor","volume":"26","author":"Holen","year":"2008","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bmc.2019.115217_b0070","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00280-009-1125-3","article-title":"Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data","volume":"65","author":"von Heideman","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmc.2019.115217_b0075","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41467-017-02349-8","article-title":"Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes","volume":"9","author":"Neggers","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2019.115217_b0080","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1021\/jm400186h","article-title":"Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors","volume":"56","author":"Zheng","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115217_b0085","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1021\/jm4008664","article-title":"Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors","volume":"56","author":"Zheng","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115217_b0090","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1016\/j.bmcl.2013.06.090","article-title":"Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)","volume":"23","author":"Dragovich","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115217_b0095","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1016\/j.bmcl.2013.08.074","article-title":"Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)","volume":"23","author":"Zheng","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115217_b0100","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bmcl.2013.12.062","article-title":"Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)","volume":"24","author":"Dragovich","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115217_b0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bmcl.2013.11.006","article-title":"Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors","volume":"24","author":"Zheng","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115217_b0110","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1016\/j.bmcl.2016.04.039","article-title":"Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies","volume":"26","author":"Clark","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115217_b0115","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1021\/acs.jmedchem.6b00324","article-title":"Structure-based design of potent nicotinamide phosphoribosyltransferase inhibitors with promising in vitro and in vivo antitumor activities","volume":"59","author":"Bai","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115217_b0120","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.bmcl.2013.04.040","article-title":"Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties","volume":"23","author":"Gunzner-Toste","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115217_b0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acsmedchemlett.7b00414","article-title":"Dual NAMPT\/HDAC inhibitors as a new strategy for multitargeting antitumor drug discovery","volume":"9","author":"Chen","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115217_b0130","doi-asserted-by":"crossref","first-page":"7965","DOI":"10.1021\/acs.jmedchem.7b00467","article-title":"Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) dual inhibitors","volume":"60","author":"Dong","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115217_b0135","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1747-0285.2006.00384.x","article-title":"PHASE: a novel approach to pharmacophore modeling and 3D database searching","volume":"67","author":"Dixon","year":"2006","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2019.115217_b0140","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1021\/ci900212v","article-title":"Novel method for generating structure-based pharmacophores using energetic analysis","volume":"49","author":"Salam","year":"2009","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2019.115217_b0145","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/bioinformatics\/bts249","article-title":"DecoyFinder: an easy-to-use python GUI application for building target-specific decoy sets","volume":"28","author":"Cereto-Massagu\u00e9","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bmc.2019.115217_b0150","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1021\/ci600426e","article-title":"Evaluating virtual screening methods: good and bad metrics for the \u201cearly recognition\u201d problem","volume":"47","author":"Truchon","year":"2007","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2019.115217_b0155","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1021\/ci800072r","article-title":"Virtual screening using PLS discriminant analysis and ROC curve approach: an application study on PDE4 inhibitors","volume":"48","author":"Rizzi","year":"2008","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2019.115217_b0160","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein\u2212ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115217_b0165","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1126\/science.1171641","article-title":"Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis","volume":"324","author":"Ramsey","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bmc.2019.115217_b0170","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bmc.2019.115217_b0175","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","article-title":"Pharmacophore modeling and applications in drug discovery: challenges and recent advances","volume":"15","author":"Yang","year":"2010","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2019.115217_b0180","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1016\/j.bmc.2012.04.048","article-title":"Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP)","volume":"20","author":"Banoglu","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2019.115217_b0185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jmgm.2019.02.014","article-title":"Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors","volume":"89","author":"Eren","year":"2019","journal-title":"J Mol Graph Model"},{"issue":"Suppl 1","key":"10.1016\/j.bmc.2019.115217_b0190","first-page":"S83","article-title":"Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests","volume":"29","author":"Florkowski","year":"2008","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.bmc.2019.115217_b0195","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/ci049714+","article-title":"ZINC\u2013a free database of commercially available compounds for virtual screening","volume":"45","author":"Irwin","year":"2005","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2019.115217_b0200","article-title":"Discovery of novel inhibitors and fluorescent probe targeting NAMPT","volume":"5","author":"Wang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2019.115217_b0205","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1210\/jc.2009-2148","article-title":"Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease","volume":"95","author":"Dahl","year":"2010","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619315123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619315123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:05:07Z","timestamp":1760835907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089619315123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0968089619315123"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115217","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115217"}}